Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MVR C5252

Next Previous
X
Search
Drug Profile

MVR C5252

Alternative Names: C-5252; MVR-C5252; T-5 - ImmVira Pharma

Latest Information Update: 06 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immvira Pharma
  • Class Antineoplastics; Gene therapies; Immunotherapies; Interleukins; Monoclonal antibodies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; Interleukin-12 expression stimulants; Programmed cell death 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Glioblastoma; Glioma

Most Recent Events

  • 11 Jun 2024 Phase-I clinical trials in Glioma (Second-line therapy or greater) in USA (Intratumoural), (NCT06126744)
  • 05 Apr 2024 Adverse events and pharmacodynamics data from the preclinical studies in Glioblastoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 29 Mar 2023 National Medical Products Administration (NMPA) recommends approval of MVR C5252 for malignant glioma in China

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top